Navigation Links
£34M injection offers new hope for anti-cancer medicines
Date:4/11/2014

The prospect of four new cancer medicines becoming a reality for patients has taken a huge step forward with the announcement of the largest healthcare investment by a European private biotech company in over a year.

Patients with advanced cancer are already benefiting from the first of these new agents, and three more new agents will follow in the next 18-24 months.

Edinburgh based biopharmaceutical company, NuCana, has announced a new 34M investment to develop its portfolio of anti-cancer medicines based on ProTide technology.

ProTides is a platform developed by Professor Chris McGuigan and his team at Cardiff University's School of Pharmacy and Pharmaceutical Sciences. ProTides are specifically designed to bypass key cancer cell resistance pathways that limit the efficacy of so many of today's anti-cancer drugs.

The funds will be used to advance and expand the clinical programme for NuCana's lead product, Acelarin, which has shown exceptional results in patients with a broad range of advanced and progressive cancers that were resistant to all conventional therapies.

Acelarin will be developed initially for patients with pancreatic, biliary, lung and ovarian cancers. In addition, the funding means the company plans to bring a second ProTide (NUC-3373) into the clinic later this year, with two further ProTides scheduled for 2015.

"It is very exciting to watch a new medicine emerge, from a theoretical idea, through chemical synthesis in our laboratory here in Cardiff and now as a new treatment for patients with cancer" according to Professor McGuigan, who developed the ProTide technology.

"This 34M investment is extremely satisfying and an endorsement of our work with NuCana. Over the last decade this represents the 14th largest private biotech round globally and the largest ever in the UK," he added.

The financing is led by a new investor, US based venture capital firm Sofinnova Ventures. The deal was completed by substantial investments from the largest shareholder, Paris based Sofinnova Partners, alongside other existing major investors Morningside Ventures, Alida Capital International and the Scottish Investment Bank.

NuCana has exclusive worldwide rights to the pioneering ProTide technology in cancer. This technology creates compounds that bypass key resistance mechanisms associated with anti-cancer drugs.

"We are delighted to be working with Chris McGuigan and the team in Cardiff. Over the years we have had a very constructive and productive collaboration with Cardiff University that is now bringing real benefits to patients," said Hugh S Griffith, the Co-Founder and CEO of NuCana.

Professor McGuigan added: "NuCana's ProTide platform has the potential to deliver to patients novel, first-in-class anti-cancer medicines. We are excited to be working with the company's experienced leadership team in the development programme.

"This investment is a real vote of confidence in our research and its application by NuCana. Together this brings real potential for developing new and powerful medicines to treat cancer."


'/>"/>

Contact: Chris McGuigan
mcguigan@cardiff.ac.uk
07-969-235-241
Cardiff University
Source:Eurekalert

Related biology news :

1. Toxic injection with elastic band
2. HCG Injections and B12 shots now in stock at US Vitamin Injections Site
3. Evolution of an outbreak: Complications from contaminated steroid injections
4. Media advisory: Brain cell injections may quiet epileptic seizures
5. Cancer vaccines self-sabotage, channel immune attack to injection site
6. Numerical study suggests subsea injection of chemicals didnt prevent oil from rising to sea surface
7. Study suggests different organ-derived stem cell injections improve heart function
8. Protein injection points to muscular dystrophy treatment
9. Laser-powered needle promises pain-free injections
10. Study in mice discovers injection of heat-generating cells reduces belly fat
11. Pain relief with PAP injections may last 100 times longer than a traditional acupuncture treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2016)... "Increase in mobile transactions is driving the ... market is expected to grow from USD 4.03 billion ... a CAGR of 29.3% between 2016 and 2022. The ... demand for smart devices, government initiatives, and increasing penetration ... is expected to grow at a high rate during ...
(Date:12/8/2016)... Dec. 8, 2016  Singulex, Inc., the leader in ... entered into a license and supply agreement with Thermo ... agreement provides Singulex access to Thermo Scientific BRAHMS PCT ... is used to diagnose systemic bacterial infection and ... to aid in assessing the risk of critically ...
(Date:12/7/2016)... , Dec. 7, 2016   Avanade ... successful Formula One teams in history, exploit biometric data ... stop performance and maintain the competitive edge against their ... 2016. Avanade has worked with Williams ... range of biometric data (heart rate, breathing rate, temperature ...
Breaking Biology News(10 mins):
(Date:1/23/2017)... , ... January 23, 2017 , ... ... at the Caribbean Neurosciences Symposium (CANS) annual meeting in Montego Bay, Jamaica from ... and host a hands-on workshop for surgeons to experience the simplicity of the ...
(Date:1/21/2017)... ... January 20, 2017 , ... Nipro Corporation (Osaka, Japan) and ... under which Nipro will receive exclusive marketing and sales rights for all non-OEM Transonic ... for hemodialysis patients in Japan, the new Nipro - Transonic JV is a natural ...
(Date:1/21/2017)... 20, 2017 Bioptix, Inc. (Nasdaq: ... that on January 14, 2017 the Board of Directors ... Company will terminate certain employees associated with the September ... Company commenced terminations on January 16, 2017 and terminations ... Company may pay severance benefits in certain circumstances of ...
(Date:1/20/2017)... PA (PRWEB) , ... January 20, 2017 , ... The ... transforming healthcare treatment options for patients. Vironika, a spin out from The Wistar Institute, ... both taking lab space at 3624 Market Street. , Vironika is developing a ...
Breaking Biology Technology: